Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma

NCT07283679 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Recurrent B-Cell Non-Hodgkin Lymphoma
Refractory B-cell Non-Hodgkin Lymphoma

Interventions

DRUG: ONC-PluReceptor NK cells

Sponsor

M.D. Anderson Cancer Center